In contrast to MCL, SIRT3 acts as an oncogene in DLBCL by regulating the metabolic pathways of cancer cells and increasing the activity of isocitrate dehydrogenase 2 (IDH2) [205]. This evidence concerns the gene SIRT3 and diffuse large B-cell lymphoma.